Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0143-0406 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| NNC0143-0406 | EXPERIMENTAL | - |
| Insulin aspart | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC0143-0406 | DRUG | Administered subcutaneously (s.c. under the skin) |
| Insulin Aspart | DRUG | Administered subcutaneously (s.c. under the skin) |
Inclusion Criteria: * Male or female aged 18-55 years (both inclusive) at the time of signing informed consent * Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior to the day of screening * Treated with continuous subcutaneous insulin infusion at least 90 days pri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NNC0143-0406 is an investigational small molecule being developed by Novo Nordisk A/S for the treatment of diabetes, specifically type 1 diabetes. It is administered subcutaneously and is currently in Phase 1 clinical development. The drug is not approved and remains under investigation for its safety, tolerability, pharmacokinetics, and pharmacodynamics.
NNC0143-0406 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with type 1 diabetes.
NNC0143-0406 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving patients with type 1 diabetes. The drug is investigational and has not yet received regulatory approval for any use.
NNC0143-0406 has been studied in two completed Phase 1 trials: NCT02612844, which investigated safety, tolerability, pharmacokinetics, and pharmacodynamics in 48 male subjects with type 1 diabetes, and NCT02938572, a proof-of-principle trial in 47 subjects with type 1 diabetes. Both trials were conducted in Austria.
NNC0143-0406 is the sole name provided for this investigational drug. No alternative names have been reported. It is a small molecule being developed by Novo Nordisk for type 1 diabetes and is currently in Phase 1 clinical trials.